What you Need to Know About Denosumab (Xgeva)

Xgeva is used in men with advanced and metastatic prostate cancer with bone metastases for the prevention of developing additional skeletal-related events (not to be confused with bone mineral density). In a phase 3 trial, the 147 Study, evaluating denosumab (Xgeva) versus placebo 1,432 men with castrate-resistant prostate cancer demonstrated that Xgeva improved median bone [...]

Denosumab for the Prevention of Skeletal Events in Men with Castration-Resistant Advanced Prostate Cancer

From: the 2014 ASCO GU Meeting Abstract No: 35 Researchers have found in a randomized controlled trial of men with metastatic castration-resistant prostate cancer (mCRPC) the use of the treatment denosumab was superior to the more commonly used zoledronic acid (ZA) for reducing skeletal-related events (SRE). SREs are defined as a pathological fracture, surgery or [...]

Zoledronic Acid (ZA) in Castrate Sensitive Prostate Cancer Does Not Prove To Be Advantageous

One thing I have noticed at some of the support groups I run is that there seems to be a very uneven distribution of when men start taking Zoledronic Acid (ZA). Hormone therapy (ADT) has many negative side effects and the loss of bone mineral density (thinning of the bones) that ZA (and similar drugs) [...]

Early Use of Zoledronic Acid (Zometa) in Men with Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance).

We have long known that Zoledronic Acid (Zometa) decreases a man’s risk of developing skeletal-related events (SREs) in men with castration-resistant advanced prostate cancer (CRPC) and bone metastases. In a phase III study that evaluated efficacy and safety of earlier treatment with Zometa in men with advanced prostate cancer which is still castration-sensitive found that [...]

From ASCO 2013 – Updated Analysis of radium-223 dichloride (Ra-223) impact on skeletal-related events (SRE) from the phase III randomized trial (ALSYMPCA).

Ra-223 (Alpharadin)is an alpha-pharmaceutical targeting bone metastases (mets) with high-energy, short-range (< 100 ?m) alpha-particles. Currently it has been submitted to the FDA for approval, which we hope will happen by August 2013. In the phase 3, double-blind, randomized, multinational ALSYMPCA study, Ra-223 significantly improved overall survival (OS) in men with castrate resistant advanced prostate [...]

Go to Top